DA
BPMC

Duality Advisers’s Blueprint Medicines BPMC Stock Holding History

Duality Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,917
Closed -$761K – 614
2022
Q1 		$761K Buy
+11,917
New +$855K 0.08% 390
2021
Q3 		– Sell
-9,796
Closed -$862K – 543
2021
Q2 		$862K Buy
+9,796
New +$898K 0.08% 359
2021
Q1 		– Sell
-4,845
Closed -$543K – 539
2020
Q4 		$543K Buy
+4,845
New +$511K 0.04% 434

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Duality Advisers's BPMC Position: Q2 2022 in Review

Duality Advisers sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 11,917 shares — an estimated $761K sold.

Duality Advisers first reported a position in BPMC in Q4 2020 and held it in 3 quarters. The position peaked at $862K in Q2 2021. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

  • Duality Advisers reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
  • Duality Advisers sold 11,917 Blueprint Medicines shares in Q2 2022, an estimated $761K.
  • Duality Advisers first reported a position in Blueprint Medicines in Q4 2020 and held it in 3 quarters.
  • Duality Advisers's Blueprint Medicines position peaked at $862K in Q2 2021.
  • 237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Duality Advisers's 13F filing for Q2 2022, filed 8 Aug 2022.